Abstract
Background Healthcare workers’ (HCWs’) travel-related anxiety needs to be assessed in light of the emergence of SARS-CoV-2 mutations.
Methods An online, cross-sectional questionnaire among HCWs between December 21, 2020 to January 7, 2021. The outcome variables were HCWs’ knowledge and awareness of the SARS-CoV-2 B.1.1.7 lineage, and its associated travel worry and Generalized Anxiety Disorder (GAD-7) score.
Results A total of 1,058 HCWs completed the survey; 66.5% were female, 59.0% were nurses. 9.0% indicated they had been previously diagnosed with COVID-19 themselves. Regarding the B.1.1.7 lineage, almost all (97.3%) were aware of its emergence, 73.8% were aware that it is more infectious, 78.0% thought it causes more severe disease, and only 50.0% knew that current COVID-19 vaccines are effective in preventing it. Despite this, 66.7% of HCWs were not registered to receive the vaccine. HCWs’ most common source of information about the new variant was social media platforms (67%), and this subgroup was significantly more worried about travelling. Nurses were more worried than physicians (P=0.001); additionally, those who had not travelled in the previous 3 months and those who had not received or registered for the COVID-19 vaccine were also significantly more worried (P = 0.037 and P < 0.001, respectively).
Conclusions Most HCWs were aware of the emergence of SARS-CoV-2 B.1.1.7 variant and expressed substantial travel worries. Increased worry levels were found among HCWs who used social media as their main source of information, those with lower levels of COVID-19 vaccine uptake, and those with higher GAD-7 scores. Utilization of official social media platforms could improve accurate information dissemination among HCWs regarding the pandemic’s evolving mutations. Targeted vaccine campaigns are warranted to assure HCWs about the efficacy of COVID-19 vaccines toward SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are grateful to the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board, King Saud University, Riyadh, Saudi Arabia, approval #20/0065/IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Consent for publication: All authors gave their consent for publication.
Availability of data and materials: All the data for this study will be made available upon reasonable request.
Funding: The authors are grateful to the Deanship of Scientific Research, King Saud University, for funding through the Vice Deanship of Scientific Research Chairs.
Conflict of interest: None declared.
Ethics approval and consent to participate: The study was approved by the institutional review board of King Saud University (approval #20/0065/IRB).
Author emails Mohamad-Hani Temsah (MHT): PO BOX 2925, Riyadh 11461, Saudi Arabia mtemsah{at}ksu.edu.sa
Mazin Barry (MB): PO BOX 2925, Riyadh 11461, Saudi Arabia mbarry{at}ksu.edu.sa
Fadi Aljamaan (FAJ): PO BOX 2925, Riyadh 11461, Saudi Arabia faljamaan{at}ksu.edu.sa
Abdullah N Alhuzaimi (ANH): PO BOX 2925, Riyadh 11461, Saudi Arabia aalhuzaimi{at}ksu.edu.sa
Ayman Al-Eyadhy (AAE): PO BOX 2925, Riyadh 11461, Saudi Arabia aleyadhy{at}ksu.edu.sa
Basema Saddik (BS): PO Box 27272, Sharjah, United Arab Emirates bsaddik{at}sharjah.ac.ae
Fahad Alsohime (FAS): PO BOX 2925, Riyadh 11461, Saudi Arabia Falsohime{at}ksu.edu.sa
Ali Alhaboob (AAH): PO BOX 2925, Riyadh 11461, Saudi Arabia drhbooob{at}gmail.com
Khalid Alhasan (KAH): PO BOX 2925, Riyadh 11461, Saudi Arabia kalhasan{at}ksu.edu.sa
Ali Alaraj (AAA): PO BOX 12471, Riyadh, Saudi Arabia al_araj{at}hotmail.com
Rabih Halwani (RH): PO Box 27272, Sharjah, United Arab Emirates rhalwani{at}sharjah.ac.ae
Amr Jamal (AJ): PO BOX 2925, Riyadh 11461, Saudi Arabia amrjamal{at}ksu.edu.sa
Nurah Alamro (NA): PO BOX 2925, Riyadh 11461, Saudi Arabia nmalamro{at}ksu.edu.sa
Reem Temsah (RT): PO Box 14135, Riyadh 11424, Saudi Arabia rtemsah{at}alfaisal.edu
Shelaweeh Alanazi (SA): PO BOX 2925, Riyadh 11461, Saudi Arabia salenizi{at}ksu.edu.sa
Fahad Alzamil (FAZ): PO BOX 2925, Riyadh 11461, Saudi Arabia fzamil{at}ksu.edu.sa
Ali Alsomaily (AAS): PO BOX 2925, Riyadh 11461, Saudi Arabia ali.somily{at}gmail.com
Jaffar A. Al-Tawfiq (JT): PO Box 11705, Dhahran 31311, Saudi Arabia jaltawfi{at}yahoo.com
Data Availability
All the data for this study will be made available upon reasonable request.
Abbreviations
- CDC
- Centers for Disease Control and Prevention
- COVID-19
- Coronavirus disease 2019
- GAD-7
- Generalized Anxiety Disorder Assessment
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- WHO
- World Health Organization
